BIOMEA FUSION INC Acción · US09077A1060 · BMEA (XNAS) Estados Unidos · Healthcare — cotizaciones y precios en tiempo real, datos de la empresa, dividendos, fundamentales y análisis de cartera con IA en MoneyPeak

Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.